Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Issue 2 (November 2016)

• Record Type: Journal Article
• Authors: Johnson, Skyler Bryce; Soulos, Pamela R.; Shafman, Timothy D.; Mantz, Constantine A.; Dosoretz, Arie P.; Ross, Rudi; Finkelstein, Steven E.; Collins, Sean P.; Suy, Simeng; Brower, Jeffrey V.; Ritter, Mark A.; King, Christopher R.; Kupelian, Patrick A.; Horwitz, Eric M.; Pollack, Alan; Abramowitz, Matthew C.; Hallman, Mark A.; Faria, Sergio; Gross, Cary P.; Yu, James B.
• Is Part Of: Radiotherapy and oncology. Volume 121:Issue 2(2016:Nov.)
• Page Start: 294
• Page End: 298
• Publication Date: 2016-11
• Subjects: Prostate cancer -- Radiation -- SBRT -- Hypofractionated -- Quality of life; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2016.10.013
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background and purpose: Evaluate changes in bowel, urinary and sexual patient-reported quality of life following treatment with moderately hypofractionated radiotherapy (<5 Gray/fraction) or stereotactic body radiation therapy (SBRT;5–10 Gray/fraction) for prostate cancer. Materials and methods: In a pooled multi-institutional analysis of men treated with moderate hypofractionation or SBRT, we compared minimally detectable difference in bowel, urinary and sexual quality of life at 1 and 2 years using chi-squared analysis and logistic regression. Results: 378 men received moderate hypofractionation compared to 534 men who received SBRT. After 1 year, patients receiving moderate hypofractionation were more likely to experience worsening in bowel symptoms (39.5%) compared to SBRT (32.5%; p = .06), with a larger difference at 2 years (37.4% versus 25.3%, p = .002). Similarly, patients receiving moderate fractionation had worsening urinary symptom score compared to patients who underwent SBRT at 1 and 2 years (34.7% versus 23.1%, p < .001; and 32.8% versus 14.0%, p < .001). There was no difference in sexual symptom score at 1 or 2 years. After adjusting for age and cancer characteristics, patients receiving SBRT were less likely to experience worsening urinary symptom scores at 2 years (odds ratio: 0.24[95%CI: 0.07–0.79]). Conclusions: Patients who received SBRT or moderate hypofractionation have similar patient-reported change in bowel and sexual symptoms, although there was worse change in urinary symptoms for patients receiving moderate hypofractionation.